Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Farmacia Hospitalaria
versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343
Resumen
MANSO, Gloria et al. Medicines under additional monitoring in the European Union. Farm Hosp. [online]. 2019, vol.43, n.1, pp.19-23. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.11041.
Objective:
The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the authorized dispensing conditions; the pharmacological groups to which they belong; and their post-authorisation safety.
Method:
We analysed the list published by the European Medicines Agency in January 2017 (EMA/245297/2013 Rev.41). Information for the analysis was obtained from the web sites of the European Medicines Agency and the Spanish Agency of Medicines and Medical Devices.
Results:
We assessed 316 medicines subject to additional monitoring. The most common criterion used to assign a medicine as being subject to additional monitoring was it being a new active substance (n = 197 (62.3%)). Other common criteria were requiring a post-authorisation safety study (n = 52 (16.5%)) and being a biologic medicine but not a new active substance (n = 49 (15.5%)). Regarding dispensing conditions, nearly 66% of these medicines were authorized under restricted conditions. Until January 2017, the Spanish Agency of Medicines and Medical Device published 14 safety reports related to medicines subject to additional monitoring.
Conclusions:
The group of medicines subject to additional monitoring mainly includes new active substances. The most common pharmacological group is antineoplastic and immunomodulating agents. The post-authorisation safety study has already produced information published by the Spanish Agency of Medicines and Medical Devices.
Palabras clave : Drug monitoring; European Union; Pharmacovigilance; Biosimilar pharmaceuticals; Mandatory reporting.